Price T Rowe Associates Inc Blueprint Medicines Corp Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,387,267 shares of BPMC stock, worth $512 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
5,387,267
Previous 5,873,392
8.28%
Holding current value
$512 Million
Previous $633 Million
21.28%
% of portfolio
0.06%
Previous 0.08%
Shares
16 transactions
Others Institutions Holding BPMC
# of Institutions
352Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$636 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$632 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$377 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$263 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.67MShares$159 Million0.4% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.68B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...